ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Hyponatremia Promotes Cancer Growth in a Murine Xenograft Model of Neuroblastoma.International journal of molecular sciences · 2023Article
- Hyponatremia and Cancer: From Bedside to Benchside.Cancers · 2023Review
- Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer.Endocrine oncology (Bristol, England) · 2022Review
- Hyponatremia and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2021Review
- Serum sodium alterations in SARS CoV-2 (COVID-19) infection: impact on patient outcome.European journal of endocrinology · 2021Observational
- Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study.Oncology and therapy · 2020Article
- Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma.Journal of clinical medicine · 2020Article
- Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro.Endocrine · 2020Article
- The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer.Clinical Medicine Insights. Oncology · 2020Article
- Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Optimal Management.Therapeutics and clinical risk management · 2020Review
- Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study.Therapeutic advances in medical oncology · 2019Article
- Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.Targeted oncology · 2018Observational
- Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?BMC cancer · 2018Article
- The predictive potential of hyponatremia for glioblastoma patient survival.Journal of neuro-oncology · 2018Article
- Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials.American journal of clinical oncology · 2018Article
- Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Article
- Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy.Oncotarget · 2017Article
- SIAD: practical recommendations for diagnosis and management.Journal of endocrinological investigation · 2016Review
- Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives.Cancer management and research · 2016Review
- SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHyponatraemia is one of the most common tumour-related electrolyte disorders. Several clinical, histological and serum factors have been found to influence prognosis, but, to date, there are no studies focusing on the prognostic role of hyponatraemia in mesothelioma. The aim of this study was to assess the prognostic role of hyponatraemia in malignant pleural mesothelioma.
methodsWe analysed 62 consecutive patients with histologically or cytologically proven advanced malignant pleural mesothelioma undergoing chemotherapy at our institution between January 2003 and September 2013.
resultsAll patients received a first-line pemetrexed-based chemotherapy. A second-line chemotherapy was administered to 29 patients. The onset of hyponatraemia (serum sodium <135 mEq/L) during the treatment was significantly related to a worsened median overall survival (7.93 vs 13.48 months; p = 0.0069). The occurrence of hyponatraemia during first-line chemotherapy (cutoff 135 and 130 mEq/L) was significantly associated to a shorter median progression-free survival (p = 0.0214). Results were also similar in the subgroup receiving a second-line treatment. At the multivariate analysis, including haemoglobin and sodium level at the beginning of first-line chemotherapy, age, gender, smoking habit, job exposure and performance status, only hyponatraemia was found to be an independent factor (p = 0.029). Hyponatraemia was also found to be a predictive factor for both first-line chemotherapy, being related to poorer response to pemetrexed-based chemotherapy (p = 0.047) and second-line chemotherapy (p = 0.044).
conclusionOur results show that hyponatraemia might be considered a negative prognostic parameter in malignant pleural mesothelioma patients. To our knowledge, this is the first study to evaluate the association of hyponatraemia with the outcome of malignant pleural mesothelioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.